Literature DB >> 23537644

Alarin but not its alternative-splicing form, GALP (Galanin-like peptide) has antimicrobial activity.

Akihiro Wada1, Pooi-Fong Wong, Hironobu Hojo, Makoto Hasegawa, Akitoyo Ichinose, Rafael Llanes, Yoshinao Kubo, Masachika Senba, Yoshio Ichinose.   

Abstract

Alarin is an alternative-splicing form of GALP (galanin-like peptide). It shares only 5 conserved amino acids at the N-terminal region with GALP which is involved in a diverse range of normal brain functions. This study seeks to investigate whether alarin has additional functions due to its differences from GALP. Here, we have shown using a radial diffusion assay that alarin but not GALP inhibited the growth of Escherichia coli (strain ML-35). The conserved N-terminal region, however, remained essential for the antimicrobial activity of alarin as truncated peptides showed reduced killing effect. Moreover, alarin inhibited the growth of E. coli in a similar potency as human cathelicidin LL-37, a well-studied antimicrobial peptide. Electron microscopy further showed that alarin induced bacterial membrane blebbing but unlike LL-37, it did not cause hemolysis of erythrocytes. In addition, alarin is only active against the gram-negative bacteria, E. coli but not the gram-positive bacteria, Staphylococcus aureus. Thus, these data suggest that alarin has potentials as an antimicrobial and should be considered for the development in human therapeutics.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23537644     DOI: 10.1016/j.bbrc.2013.03.045

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  6 in total

Review 1.  The evolving roles of alarin in physiological and disease conditions, and its future potential clinical implications.

Authors:  Endeshaw Chekol Abebe; Misganaw Asmamaw Mengstie; Mohammed Abdu Seid; Tabarak Malik; Tadesse Asmamaw Dejenie
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-29       Impact factor: 6.055

2.  Serum Tenascin-C and Alarin Levels Are Associated with Cardiovascular Diseases in Type 2 Diabetes Mellitus.

Authors:  Mingming Li; Mengjiao Wu; Hua Zhu; Yulin Hua; Zijun Ma; Jiayi Yao; Bin Feng; Bimin Shi
Journal:  Int J Endocrinol       Date:  2022-04-21       Impact factor: 2.803

3.  Intracerebroventricular Injection of Alarin Increased Glucose Uptake in Skeletal Muscle of Diabetic Rats.

Authors:  Zhenwen Zhang; Yongkang Wu; Shudong Sheng; Lili Guo; Biao He; Penghua Fang; Mingyi Shi; Ping Bo; Yan Zhu
Journal:  PLoS One       Date:  2015-10-06       Impact factor: 3.240

4.  Circulating alarin concentrations are high in patients with type 2 diabetes and increased by glucagon-like peptide-1 receptor agonist treatment: An Consort-compliant study.

Authors:  Wenjing Hu; Xiaoyun Fan; Baoyong Zhou; Ling Li; Bo Tian; Xia Fang; Xiaohui Xu; Hua Liu; Gangyi Yang; Yongsheng Liu
Journal:  Medicine (Baltimore)       Date:  2019-07       Impact factor: 1.817

5.  Human antimicrobial peptides and proteins.

Authors:  Guangshun Wang
Journal:  Pharmaceuticals (Basel)       Date:  2014-05-13

6.  Database-Guided Discovery of Potent Peptides to Combat HIV-1 or Superbugs.

Authors:  Guangshun Wang
Journal:  Pharmaceuticals (Basel)       Date:  2013-05-27
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.